Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Germany Pharmaceuticals Market Size, Share & Trends Analysis Report By Drug Class (Anti-cancer, Anti-viral, Anti-diabetics, Anti-rheumatics), By Type, By Formulation, By Application, And Segment Forecasts, 2020 - 2027

Published by Grand View Research, Inc. Product code 963108
Published Content info 100 Pages
Delivery time: 2-3 business days
Price
Back to Top
Germany Pharmaceuticals Market Size, Share & Trends Analysis Report By Drug Class (Anti-cancer, Anti-viral, Anti-diabetics, Anti-rheumatics), By Type, By Formulation, By Application, And Segment Forecasts, 2020 - 2027
Published: September 11, 2020 Content info: 100 Pages
Description

Germany Pharmaceuticals Market Growth & Trends

The Germany pharmaceuticals market size is expected to reach USD 65.9 billion by 2027, expanding at a CAGR of 6.0%, according to a new report by Grand View Research, Inc. Factors such as the rising prevalence of acute and chronic diseases and increasing R&D expenditure by pharmaceutical companies are expected to drive the market.

Furthermore, rising clinical trials and approval of novel immune-suppressive therapies are anticipated to propel market growth. For instance, in June 2020, Sandoz International GmbH launched Dailiport capsules (generic tacrolimus) in Germany and other European countries. Dailiport capsules are indicated for adult kidney and liver transplant patients.

In addition, the export of pharmaceutical products by pharmaceutical companies in Germany to various countries is expected to fuel market growth. For instance, according to Germany Trade and Invest, in China, 22.0% of imported pharmaceutical products are from German companies.

Key players entering into strategic initiatives such as partnership, licensing, acquisition, and collaboration to expand and strengthen their regional presence is expected to boost the market growth. For instance, in November 2019, Bristol-Myers Squibb Company acquired Celgene Corporation. This acquisition was aimed at helping the company expand its oncology portfolio worldwide and develop innovative medicines.

In addition, rising funds by organizations for the development of pipeline drugs are anticipated to accelerate market growth. For instance, in January 2019, Atriva Therapeutics GmbH closed its series A financing led by Meneldor and High-Tech Grunderfonds GmbH (HTGF) for its lead drug candidate ATR-002. This drug candidate is developed against influenza infection and other respiratory infections.

Various other organizations, such as the European Cancer Organisation (ECCO), European Cancer Patient Coalition (ECPC), and European Organisation for Research and Treatment of Cancer (EORTC) provide funds for cancer research programs and treatment plans.

Furthermore, increasing the availability of generic drugs at a lower price is expected to boost the market growth. For instance, in July 2019, Sandoz of Novartis AG launched a generic version of gefitinib for locally advanced or metastatic NSCLC. The launch of the generic version is estimated to increase the number of patients treated due to the favorable cost of the drug.

Germany Pharmaceuticals Market Report Highlights

In 2019, anti-cancer was the largest-revenue holding drug class in the market owing to rising approval of new drugs and increasing research studies on new approaches to treating various cancers

Immunosuppressant product type is estimated to be the fastest-growing drug class during the forecast period owing to rising development and launch of novel immunosuppressant

Oncology application held the largest revenue share in 2019 due to the increasing prevalence of breast cancer, prostate cancer, and lung cancer

On the basis of type, the generic drugs segment is expected to be the fastest-growing segment over the forecast period due to its cost-effectiveness and expiration of patents.

Table of Contents
Product Code: GVR-4-68039-118-0

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Scope
    • 1.1.2 Country Scope
    • 1.1.3 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
      • 1.3.5.1 Data for primary interviews in Germany
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach: Commodity flow approach
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations
  • 1.9 Objectives
    • 1.9.1 Objective 1
    • 1.9.2 Objective 2
    • 1.9.3 Objective 3
    • 1.9.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Insights

Chapter 3 Germany Pharmaceuticals Market Variables, Trends, & Scope

  • 3.1 Penetration & Growth Prospect Mapping
  • 3.2 User Perspective Analysis
  • 3.3 Regulatory Framework
  • 3.4 Reimbursemnt and Pricing Analysis
  • 3.5 Export and Import of Pharmaceutical drugs
  • 3.6 Pipeline Analysis
  • 3.7 Market Dynamics
    • 3.7.1 Market Drivers Analysis
      • 3.7.1.1 Rising Patent Applications
      • 3.7.1.2 Increasing R&D Expenditure By Pharmaceutical Companies
      • 3.7.1.3 Funding By Various Orgnaizations
      • 3.7.1.4 Rising Clinical Trials And Approval Of New Drugs
      • 3.7.1.5 Increasing Prevalence Of Acute And Chronic Diseases
      • 3.7.1.6 Initiatives By Government And Organizations
    • 3.7.2 Market Restraint Analysis
      • 3.7.2.1 Unfavourable pricing and reimbursement system for manufacturers
  • 3.8 Germany Pharmaceuticals: Market Analysis Tools
    • 3.8.1 Industry Analysis - Porter's
    • 3.8.2 Pestle Analysis

Chapter 4 Germany Pharmaceuticals Market: Segment Analysis, By Drug Class, 2016 - 2027 (USD Million)

  • 4.1 Definition and Scope
  • 4.2 Drug class Market Share Analysis, 2019 & 2027
  • 4.3 Segment Dashboard
  • 4.4 Germany Pharmaceuticals Market, by Drug class, 2016 to 2027
  • 4.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027
    • 4.5.1 Anti-Cancer Drugs
      • 4.5.1.1 Anti-Cancer Drugs Market, 2016 - 2027 (USD Million)
    • 4.5.2 Anti-Diabetics
      • 4.5.2.1 Anti-Diabetics Market, 2016 - 2027 (USD Million)
    • 4.5.3 Anti-Rheumatics
      • 4.5.3.1 Anti-Rheumatics Market, 2016 - 2027 (USD Million)
    • 4.5.4 Vaccines
      • 4.5.4.1 Vaccines Market, 2016 - 2027 (USD Million)
    • 4.5.5 Anti-Viral
      • 4.5.5.1 Anti-Viral Market, 2016 - 2027 (USD Million)
    • 4.5.6 Immunosuppressants
      • 4.5.6.1 Immunosuppressants Market, 2016 - 2027 (USD Million)
    • 4.5.7 Bronchodilators
      • 4.5.7.1 Anti-Rheumatics Market, 2016 - 2027 (USD Million)
    • 4.5.8 Dermatological
      • 4.5.8.1 Dermatological Market, 2016 - 2027 (USD Million)
    • 4.5.9 Anti-Hypertensive
      • 4.5.9.1 Anti-Hypertensive Market, 2016 - 2027 (USD Million)
    • 4.5.10 Others
      • 4.5.10.1 Others Market, 2016 - 2027 (USD Million)

Chapter 5 Germany Pharmaceuticals Market: Segment Analysis, By Application, 2016 - 2027 (USD Million)

  • 5.1 Definition and Scope
  • 5.2 Application Market Share Analysis, 2019 & 2027
  • 5.3 Segment Dashboard
  • 5.4 Germany Pharmaceuticals Market, by Application, 2016 to 2027
  • 5.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027
    • 5.5.1 Oncology
      • 5.5.1.1 Oncology Market, 2016 - 2027 (USD Million)
      • 5.5.1.2 Breast Cancer
      • 5.5.1.2.1 Breast Cancer Market, 2016 - 2027 (USD Million)
      • 5.5.1.3 Lung Cancer
      • 5.5.1.3.1 LUNG CANCER MARKET, 2016 - 2027 (USD Million)
      • 5.5.1.4 Colorectal Cancer
      • 5.5.1.4.1 COLORECTAL CANCER MARKET, 2016 - 2027 (USD Million)
      • 5.5.1.5 Ovarian Cancer
      • 5.5.1.5.1 OVARIAN CANCER MARKET, 2016 - 2027 (USD Million)
      • 5.5.1.6 Prostate Cancer
      • 5.5.1.6.1 PROSTATE CANCER MARKET, 2016 - 2027 (USD Million)
      • 5.5.1.7 Others
      • 5.5.1.7.1 OTHERS MARKET, 2016 - 2027 (USD Million)
    • 5.5.2 Infectious Disease
      • 5.5.2.1 Infectious Disease Market, 2016 - 2027 (USD Million)
    • 5.5.3 Cardiovascular Disease
      • 5.5.3.1 Cardiovascular Disease Market, 2016 - 2027 (USD Million)
    • 5.5.4 Cenral Nervous System
      • 5.5.4.1 Central Nervous System Market, 2016 - 2027 (USD Million)
    • 5.5.5 Immunology
      • 5.5.5.1 Immunology Market, 2016 - 2027 (USD Million)
    • 5.5.6 Metabolic Disorders
      • 5.5.6.1 Metabolic Disorders Market, 2016 - 2027 (USD Million)
    • 5.5.7 Gastrointestinal Disease
      • 5.5.7.1 Gastrointestinal Disease Market, 2016 - 2027 (USD Million)
    • 5.5.8 Opthalmology
    • 5.5.8 1 Opthalmology Market, 2016 - 2027 (USD Million)
    • 5.5.9 Dermatology
      • 5.5.9.1 Dermatology Market, 2016 - 2027 (USD Million)
    • 5.5.10 Others
      • 5.5.10.1 Others market, 2016 - 2027 (USD Million)

Chapter 6 Germany Pharmaceuticals Market: Segment Analysis, By Type, 2016 - 2027 (USD Million)

  • 6.1 Definition and Scope
  • 6.2 Type Market Share Analysis, 2019 & 2027
  • 6.3 Segment Dashboard
  • 6.4 Germany Pharmaceuticals Market, by Type, 2016 to 2027
  • 6.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027
    • 6.5.1 Generics
      • 6.5.1.1 Generics Market, 2016 - 2027 (USD Million)
    • 6.5.2 Branded
      • 6.5.2.1 Branded market, 2016 - 2027 (USD Million)

Chapter 7 Germany Pharmaceuticals Market: Segment Analysis, By Formulations, 2016 - 2027 (USD Million)

  • 7.1 Definition and Scope
  • 7.2 Formulations Market Share Analysis, 2019 & 2027
  • 7.3 Segment Dashboard
  • 7.4 Germany Pharmaceuticals Market, by Formulations, 2016 to 2027
  • 7.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027
    • 7.5.1 Solid Formulations
      • 7.5.1.1 Solid Formulations Market, 2016 - 2027 (USD Million)
      • 7.5.1.2 Tablets
      • 7.5.1.2.1 Tablets Market, 2016 - 2027 (USD Million)
      • 7.5.1.3 Capsules
      • 7.5.1.3 1 Capsules Market, 2016 - 2027 (USD Million)
      • 7.5.1.4 Others
      • 7.5.1.4.1 Others Market, 2016 - 2027 (USD Million)
    • 7.5.2 Liquid And Semi-Solid Formulations
      • 7.5.2.1 Liquid And Semi-Solid Formulations Market, 2016 - 2027 (USD Million)
      • 7.5.2.2 Oral
      • 7.5.2.2.1 Oral Market, 2016 - 2027 (USD Million)
      • 7.5.2.3 Topical
      • 7.5.2.3.1 Topical Market, 2016 - 2027 (USD Million)
      • 7.5.2.4 Sublingual And Buccal
      • 7.5.2.4.1 Sublingual And Buccal Market, 2016 - 2027 (USD Million)
      • 7.5.2.5 Rectal
      • 7.5.2.5.1 Rectal Market, 2016 - 2027 (USD Million)
      • 7.5.2.6 Parenteral
      • 7.5.2.6.1 Parenteral Market, 2016 - 2027 (USD Million)

Chapter 8 Germany Pharmaceuticals Market - Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 8.1.1 Ansoff Matrix
    • 8.1.2 Heat Map Analysis
  • 8.2 Company Categorization
    • 8.2.1 Innovators
    • 8.2.2 Market Leaders
  • 8.3 Vendor Landscape
    • 8.3.1 List Of Key Distributors And Channel Partners
    • 8.3.2 Key Customers
    • 8.3.3 Key Company Market Share Analysis, 2019
  • 8.4 Public Companies
    • 8.4.1 Company Market Position Analysis
    • 8.4.2 Company Market Share, By Region
    • 8.4.3 Competitive Dashboard Analysis
      • 8.4.3.1 Market Differentiators
  • 8.5 Private Companies
    • 8.5.1 List Of Key Emerging Companies
    • 8.5.2 Regional Map
  • 8.6 Company Profiles
    • 8.6.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.
      • 8.6.1.1 Company overview
      • 8.6.1.2 Financial performance
      • 8.6.1.3 Product benchmarking
      • 8.6.1.4 Strategic initiatives
    • 8.6.2 BAYER AG
      • 8.6.2.1 Company overview
      • 8.6.2.2 Financial performance
      • 8.6.2.3 Product benchmarking
      • 8.6.2.4 Strategic initiatives
    • 8.6.3 MERCK KGAA
      • 8.6.3.1 Company overview
      • 8.6.3.2 Financial performance
      • 8.6.3.3 Product benchmarking
      • 8.6.3.4 Strategic initiatives
    • 8.6.4 STADA ARZNEIMITTEL AG
      • 8.6.4.1 Company overview
      • 8.6.4.2 Financial performance
      • 8.6.4.3 Product benchmarking
      • 8.6.4.4 Strategic initiatives
    • 8.6.5 PFIZER INC.
      • 8.6.5.1 Company overview
      • 8.6.5.2 Product benchmarking
    • 8.6.6 ABBOTT
      • 8.6.6.1 Company overview
      • 8.6.6.2 Financial performance
      • 8.6.6.3 Product benchmarking
      • 8.6.6.3 Strategic initiatives
    • 8.6.7 ABBVIE INC.
      • 8.6.7.1 Company overview
      • 8.6.7.2 Financial performance
      • 8.6.7.3 Product benchmarking
      • 8.6.7.4 Strategic initiatives
    • 8.6.8 FRESENIUS KABI
      • 8.6.8.1 Company overview
      • 8.6.8.2 Financial performance
      • 8.6.8.3 Product benchmarking
      • 8.6.8.4 Strategic initiatives
    • 8.6.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
      • 8.6.9.1 Company overview
      • 8.6.9.2 Financial performance
      • 8.6.9.3 Product benchmarking
      • 8.6.9.4 Strategic initiatives
    • 8.6.10 NOVARTIS AG
      • 8.6.10.1 Company overview
      • 8.6.10.2 Financial performance
      • 8.6.10.3 Product benchmarking
      • 8.6.10.4 Strategic initiatives
    • 8.6.11 SANOFI
      • 8.6.11.1 Company overview
      • 8.6.11.2 Financial performance
      • 8.6.11.3 Product benchmarking
      • 8.6.11.4 trategic initiatives
    • 8.6.12 JOHNSON & JOHNSON SERVICES, INC.
      • 8.6.12.1 Company overview
      • 8.6.12.2 Financial performance
      • 8.6.12.3 Product benchmarking
      • 8.6.12.4 Strategic initiatives
    • 8.6.13 GLAXOSMITHKLINE PLC
      • 8.6.13.1 Company overview
      • 8.6.13.2 Financial performance
      • 8.6.13.3 Product benchmarking
      • 8.6.13.4 Strategic initiatives
    • 8.6.14 ASTRAZENECA
      • 8.6.14.1 Company overview
      • 8.6.14.2 Financial performance
      • 8.6.14.3 Product benchmarking
      • 8.6.14.4 Strategic initiatives
    • 8.6.15 CELGENE CORPORATION
      • 8.6.15.1 Company overview
      • 8.6.15.2 Financial performance
      • 8.6.15.3 Product benchmarking
      • 8.6.15.4 Strategic initiatives
    • 8.6.16 AMGEN INC.
      • 8.6.16.1 Company overview
      • 8.6.16.2 Financial performance
      • 8.6.16.3 Product benchmarking
      • 8.6.16.4 Strategic initiatives
    • 8.6.17 NOVO NORDISK A/S
      • 8.6.17.1 Company overview
      • 8.6.17.2 Financial performance
      • 8.6.17.3 Product benchmarking
      • 8.6.17.4 Strategic initiatives
    • 8.6.18 ELI LILLY AND COMPANY
      • 8.6.18.1 Company overview
      • 8.6.18.2 Financial performance
      • 8.6.18.3 Product benchmarking
      • 8.6.18.4 Strategic initiatives
    • 8.6.19 ALLERGAN
      • 8.6.19.1 Company overview
      • 8.6.19.2 Financial performance
      • 8.6.19.3 Product benchmarking
      • 8.6.20.4 Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 Pipeline analysis
  • Table 4 List of key emerging companies /technology disruptors/innovators
  • Table 5 Germany pharmaceuticals market, by drug class, 2016 - 2027 (USD Million)
  • Table 6 Germany pharmaceuticals market, by application, 2016 - 2027 (USD Million)
  • Table 7 Germany oncology market, by type, 2016 - 2027 (USD Million)
  • Table 8 Germany pharmaceuticals market, by type, 2016 - 2027 (USD Million)
  • Table 9 Germany pharmaceuticals market, by formulation, 2016 - 2027 (USD Million)
  • Table 10 Germany pharmaceuticals market, by solid formulation, 2016 - 2027 (USD Million)
  • Table 11 Germany pharmaceuticals market, by liquid & semi-liquid formulation, 2016 - 2027 (USD Million)

List of Figures

  • Fig. 1 Germany pharmaceuticals market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Primary interviews in Germany
  • Fig. 6 Market research approaches
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD modeling for market share assessment
  • Fig. 9 Market formulation & validation
  • Fig. 10 Market outlook (2019)

Fig. 11 Segment Outlook (Type, 2019)

  • Fig. 12 Strategy framework
  • Fig. 13 Penetration & growth prospect mapping
  • Fig. 14 User perspective analysis
  • Fig. 15 Annual value of pharmaceuticals export from Germany (USD million) (2015 - 2018)
  • Fig. 16 German export volume in International markets (USD million) (2016)
  • Fig. 17 Number of patents granted by the EPO in Germany (2016 - 2019)
  • Fig. 18 Market driver relevance analysis (Current & future impact)
  • Fig. 19 Market restraint relevance analysis (Current & future impact)
  • Fig. 20 Porter's five forces analysis
  • Fig. 21 PESTLE analysis
  • Fig. 22 Germany Pharmaceuticals market: Drug class movement analysis
  • Fig. 23 Drug class segment dashboard
  • Fig. 24 Germany Pharmaceuticals market Drug class outlook: Key takeaways
  • Fig. 25 Anti-cancer drugs market, 2016 - 2027 (USD Million)
  • Fig. 26 Antidiabetics market, 2016 - 2027 (USD Million)
  • Fig. 27 Antirheumatics market, 2016 - 2027 (USD Million)
  • Fig. 28 Vaccines market, 2016 - 2027 (USD Million)
  • Fig. 29 Antiviral market, 2016 - 2027 (USD Million)
  • Fig. 30 Immunosuppressants market, 2016 - 2027 (USD Million)
  • Fig. 31 Bronchodilators market, 2016 - 2027 (USD Million)
  • Fig. 32 Dermatological market, 2016 - 2027 (USD Million)
  • Fig. 33 Anti-hypertensives market, 2016 - 2027 (USD Million)
  • Fig. 34 Others market, 2016 - 2027 (USD Million)
  • Fig. 35 Germany Pharmaceuticals market: Application movement analysis
  • Fig. 36 Application segment dashboard
  • Fig. 37 Germany Pharmaceuticals market application outlook: Key takeaways
  • Fig. 38 Oncology market, 2016 - 2027 (USD Million)
  • Fig. 39 Breats cancer market, 2016 - 2027 (USD Million)
  • Fig. 40 Lung cancer market, 2016 - 2027 (USD Million)
  • Fig. 41 Colorectal cancer market, 2016 - 2027 (USD Million)
  • Fig. 42 Ovarian cancer market, 2016 - 2027 (USD Million)
  • Fig. 43 Prostate cancer market, 2016 - 2027 (USD Million)
  • Fig. 44 Others market, 2016 - 2027 (USD Million)
  • Fig. 45 Infectious diseases market, 2016 - 2027 (USD Million)
  • Fig. 46 Cardiovasular diseases market, 2016 - 2027 (USD Million)
  • Fig. 47 Central nervous system market, 2016 - 2027 (USD Million)
  • Fig. 48 Immunology market, 2016 - 2027 (USD Million)
  • Fig. 49 Metabolic disorders market, 2016 - 2027 (USD Million)
  • Fig. 50 Gastrointestinal diseases market, 2016 - 2027 (USD Million)
  • Fig. 51 Respiratory diseases market, 2016 - 2027 (USD Million)
  • Fig. 52 Opthalmology market, 2016 - 2027 (USD Million)
  • Fig. 53 Dermatology market, 2016 - 2027 (USD Million)
  • Fig. 54 Others market, 2016 - 2027 (USD Million)
  • Fig. 55 Germany pharmaceuticals market: Type movement analysis
  • Fig. 56 Type segment dashboard
  • Fig. 57 Germany pharmaceuticals market type outlook: Key takeaways
  • Fig. 58 Branded market, 2016 - 2027 (USD Million)
  • Fig. 59 Generic drugs market, 2016 - 2027 (USD Million)
  • Fig. 60 Germany pharmaceuticals market: Formulations movement analysis
  • Fig. 61 Formulations segment dashboard
  • Fig. 62 Germany pharmaceuticals market formulations outlook: Key takeaways
  • Fig. 63 Solid formulation market, 2016 - 2027 (USD Million)
  • Fig. 64 Tablets market, 2016 - 2027 (USD Million)
  • Fig. 65 Capsules market, 2016 - 2027 (USD Million)
  • Fig. 66 Others market, 2016 - 2027 (USD Million)
  • Fig. 67 Liquid and semi-solid formulations market, 2016 - 2027 (USD Million)
  • Fig. 68 Oral market, 2016 - 2027 (USD Million)
  • Fig. 69 Topical market, 2016 - 2027 (USD Million)
  • Fig. 70 Sublingual & buccal market, 2016 - 2027 (USD Million)
  • Fig. 71 Rectal market, 2016 - 2027 (USD Million)
  • Fig. 72 Parenteral market, 2016 - 2027 (USD Million)
  • Fig. 73 Ansoff Matrix
  • Fig. 74 Competition Categorization
  • Fig. 75 Company market share analysis
  • Fig. 76 Company market position analysis
  • Fig. 77 Company market position analysis
  • Fig. 78 Competitive dashboard analysis
  • Fig. 79 Regional Network Map
  • Fig. 80 Strategy Framework
Back to Top